SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company advancing innovative pharmacologic therapies for refractive eye diseases, today announced key executive promotions designed to strengthen …
Category: Business
Automata Raises $45M Series C to Build the Operating System for AI-Ready Labs
LONDON–(BUSINESS WIRE)– #aiml–Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a $45 million Series C funding round led by Dimension with participation from Danaher Ve…
Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the su…
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that the U.S. Food and Drug Administration (F…
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S….
Following Merger, Advancing Sight Network and Miracles In Sight Become Precision Ocular Network
BIRMINGHAM, Ala. & CLEMMONS, N.C.–(BUSINESS WIRE)–Advancing Sight Network and Miracles In Sight today announced Precision Ocular Network as the new name and brand of their combined organization, following the merger unveiled in November. The new iden…
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis
HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)– #FDA–Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and D…
Artificial Iris Market Growth Forecast (2026-2032) Featuring Strategic Profiles of Leading Players Art Eyes, BrightOcular, Ophtec, REPER-NN, Spectrum Surgical, VEO Ophthalmics and More – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Artificial Iris Market – Global Forecast 2026-2032” has been added to ResearchAndMarkets.com’s offering. The Artificial Iris Market has shown significant growth, expanding from USD 17.71 million in 2024 to USD 19.31 millio…
Chicago Atlantic Provides $16.5 Million Term Loan to Ocular Science, Inc., a Leading Biotech Company Focused on Compounded Ophthalmic Products
CHICAGO–(BUSINESS WIRE)–Chicago Atlantic announced its role as sole arranger and administrative agent in the closing of a $16.5 million senior secured term loan for Ocular Science, Inc. (“Ocular Science”), an affiliate of OSRX, Inc. OSRX is a leading…
STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. …
In Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant "The First Treatment to Restore Vision" In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration
ALAMEDA, Calif.–(BUSINESS WIRE)–An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation’s PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain …
Diorasis Therapeutics Appoints Richard A. Kresch, MD, to Board of Directors
BOSTON–(BUSINESS WIRE)– #genetherapy–Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ophthalmic diseases, today announced the appointment of Richard A. Kresch, MD, to its Board of …
Abbelight kondigt een succesvolle Serie B-investering aan, geleid door AVANT BIO, om innovatie in beeldvorming te versnellen en toepassing in een ruimer klantenbestand op schaal te brengen
PARIJS–(BUSINESS WIRE)–Abbelight, een wereldleider en pionier in end-to-end oplossingen voor super-resolutiemicroscopie, kondigde vandaag een succesvolle Serie B-financieringsronde aan, geleid door AVANT BIO, een verstrekker van groeikapitaal die zic…
Abbelight kündigt erfolgreiche Serie-B-Finanzierungsrunde unter Federführung von AVANT BIO an, um Innovationen im Bereich Bildgebung voranzutreiben und deren Verbreitung bei einem größeren Kundenstamm zu fördern
PARIS–(BUSINESS WIRE)–Abbelight, ein Weltmarktführer und Pionier im Bereich End-to-End-Lösungen für die Superauflösungsmikroskopie, gab heute den erfolgreichen Abschluss einer Serie-B-Finanzierungsrunde unter der Leitung von AVANT BIO bekannt, einer …
Abbelight annuncia il successo dell'investimento di serie B guidato da AVANT BIO per accelerare l'innovazione dell'imaging e incrementare l'adozione da parte di un'ampia clientela
PARIGI–(BUSINESS WIRE)–Abbelight, un leader globale e un pioniere nelle soluzioni complete di microscopia a super risoluzione, oggi ha annunciato il successo di un round di finanziamento di serie B guidato da AVANT BIO, società di capitali di crescit…
Abbelight annonce le succès d’un investissement de série B mené par AVANT BIO afin d’accélérer l’innovation en imagerie et d’étendre son adoption à une clientèle plus large
PARIS–(BUSINESS WIRE)–Abbelight, leader mondial et pionnier dans le domaine des solutions complètes de microscopie à super-résolution, a annoncé aujourd’hui le succès d’un tour de financement de série B mené par AVANT BIO, une société de capital-inve…
Abbelight anuncia el exitoso cierre de una ronda de inversión Serie B liderada por AVANT BIO para acelerar la innovación en imagenología y ampliar su adopción a una base de clientes más amplia
PARÍS–(BUSINESS WIRE)–Abbelight, líder global y empresa pionera en soluciones integrales de microscopía de superresolución, anunció hoy el cierre exitoso de una ronda de financiación Serie B liderada por AVANT BIO, una firma de capital de crecimiento…
GenSight Biologics publie sa situation de trésorerie au 31 décembre 2025 et fait un point sur son activité
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (« GenSight Biologics » ou la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de…
GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (“GenSight Biologics” or the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for ret…
Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, head-to-head Phase 1b JADE clin…